View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsGreenLight Biosciences Holdings 향후 성장Future 기준 점검 2/6현재 GreenLight Biosciences Holdings 의 성장과 수익을 예측할 만큼 분석가의 범위가 충분하지 않습니다.핵심 정보-1.0%이익 성장률n/aEPS 성장률Biotechs 이익 성장24.8%매출 성장률70.7%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트22 Jul 2023최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .공시 • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.공시 • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.공시 • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.27 loss per share (vs US$9.86 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share. Net loss: US$38.2m (loss widened 14% from 3Q 2021). Revenue is forecast to grow 121% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.Seeking Alpha • Oct 12GreenLight Biosciences cutting 25% of staff as part of realignmentGreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.Recent Insider Transactions • Aug 17Independent Director recently bought US$250k worth of stockOn the 11th of August, Matthew Walker bought around 64k shares on-market at roughly US$3.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.28 loss in 2Q 2021)Second quarter 2022 results: US$0.42 loss per share (down from US$0.28 loss in 2Q 2021). Net loss: US$51.9m (loss widened 91% from 2Q 2021).공시 • Aug 13GreenLight Biosciences Holdings announced that it expects to receive $109.149981 million in funding from a group of investorsGreenLight Biosciences Holdings announced a private placement of 27,844,383 common shares at a price per share of $3.92 for gross proceeds of $109,149,981 on August 12, 2022. The transaction will include participation from accredited investors, existing institutional investors and new investors including Cummings Foundation, Inc., Endowment Arm, the FTX Foundation, Insud Pharma S.L.U., Rivas Capital LLC, Sigmas Group, SymBiosis Capital Management LLC, returning investors S2G Ventures, Bnp Paribas Funds - Ecosystem Restoration; a fund managed by BNPP Asset Management Luxembourg, Continental Grain Company Corp., Cormorant Asset Management, LP, Fall Line Capital, LLC, Morningside Ventures Limited, and certain directors and executive officers of the company.Seeking Alpha • Aug 12GreenLight Biosciences launches $109M in financingGreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.공시 • Aug 02GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 VaccineGreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability. GreenLight's process—from drug substance and lipid nanoparticle formulation to bulk drug product—can be completed in the same facility, an important capability. GreenLight's mRNA synthesis reaction had a titer of 12g/L at commercial scale and produced 650g of mRNA. The company's RNA platform allowed GreenLight to move from conceptualizing an mRNA vaccine to delivering released clinical trial material in less than two years. With the demonstration at Samsung, and with GreenLight's Covid booster vaccine clinical trial expected to start in 2022, GreenLight would be capable of supplying mRNA vaccine at a commercial scale.Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Seeking Alpha • Aug 01GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccineGreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.Board Change • Jul 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • May 18First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 loss in 1Q 2021)First quarter 2022 results: US$0.34 loss per share (down from US$0.27 loss in 1Q 2021). Net loss: US$38.2m (loss widened 49% from 1Q 2021).Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Apr 05GreenLight Biosciences: Synthesizing Cell-Free RNAGreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.공시 • Mar 30GreenLight Biosciences Appoints Barney Graham as Human Health Scientific Advisory BoardGreenLight Biosciences announced Barney Graham to its Human Health Scientific Advisory Board. The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service. Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure.공시 • Feb 08GreenLight Biosciences Holdings Announces Management ChangesOn February 2, 2022, Environmental Impact Acquisition Corp. (ENVI), consummated the previously announced business combination with GreenLight Biosciences Inc. (GreenLight), pursuant to the terms of the business combination agreement, dated August 9, 2021 (the Business Combination Agreement), among ENVI, GreenLight and Honey Bee Merger Sub Inc. (“Merger Sub). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into GreenLight, with GreenLight surviving the merger as a wholly owned subsidiary of ENVI (the Merger or Business Combination). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (GreenLight Holdings) and became a public benefit corporation. Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Daniel Coyne, Marc Marano, Deval L. Patrick, David Brewster and Dean Seavers ceased serving as a director of GreenLight Holdings, and each of Daniel Coyne and Marc Marano ceased serving as an executive officer of GreenLight Holdings.Board Change • Feb 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Observer Colin Steen was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측NasdaqGM:GRNA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202422-161-166N/A112/31/2023N/A-166-177N/A13/31/202310-157-146-118N/A12/31/20227-167-163-137N/A9/30/20224-163-164-137N/A6/30/20223-154-143-122N/A3/31/20222-129-131-120N/A12/31/20212-112-107-92N/A9/30/20211-86-98-84N/A6/30/20212-89-80-68N/A3/31/20212-75-70-58N/A12/31/20202-53-57-47N/A12/31/20193-37-28-26N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: GRNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: GRNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: GRNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: GRNA 의 수익(연간 70.7%)이 US 시장(연간 12.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: GRNA 의 수익(연간 70.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: GRNA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/07/25 05:38종가2023/07/21 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스GreenLight Biosciences Holdings는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Robert BurlesonCanaccord Genuity
공시 • Jul 26GreenLight Biosciences Holdings(NasdaqGM:GRNA) dropped from NASDAQ Composite IndexGreenLight Biosciences Holdings has been dropped from NASDAQ Composite Index (^COMP) .
공시 • Jul 25+ 2 more updatesA group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders.An affiliate of Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC enter into a preliminary non-binding proposal to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders for $84.1 million on March 29, 2023. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC entered into a definitive agreement to acquire GreenLight Biosciences Holdings (NasdaqGM:GRNA) from a group of shareholders for $45.5 million on May 29, 2023. As part of the bid, Fall Line Endurance will acquire all of the outstanding shares of common stock for $0.60 per share in cash. GreenLight’s Board of Directors through a special committee thereof (the “Special Committee”) will carefully evaluate Fall Line’s indication of interest within the context of the ongoing review of various alternatives and in consultation with any financial and legal advisors it may retain. Any definitive agreement entered into in connection with the Proposed Transaction would be subject to customary closing conditions, including approval by the Special Committee, any required stockholder approvals and approval by any applicable regulatory authorities. Pursuant to the terms of the merger agreement, and subject to the conditions set forth therein, Fall Line, together with its affiliates, agreed that it will commence a tender offer (the “Offer”) to acquire all of the outstanding shares of common stock of the Company (the “Company Common Stock”), other than certain excluded shares, for $0.30 per share (the “Offer Price”), net to the seller in cash, without interest thereon, and subject to any required withholding, upon the terms and subject to the conditions of the merger agreement. The Offer Price represents a 50% premium to the closing price of the Company’s Common Stock as of May 26, 2023, the last trading day prior to the date of this announcement. In connection with the transactions contemplated by the merger agreement, certain existing stockholders of the Company, together holding approximately 79.5% of the outstanding shares of the Company Common Stock, entered into contribution and exchange agreements pursuant to which such stockholders agreed to contribute their shares of Company Common Stock in exchange for shares of Series A-2 Preferred Stock of a newly formed holding company (the “Private Company”) that will own 100% of the Company upon the consummation of the transactions contemplated by the merger agreement. In addition, in connection with the transactions contemplated by the Merger Agreement, Fall Line and certain investors entered into a Secured Convertible Note Purchase Agreement (the “Note Purchase Agreement”), to which the Company is a third-party beneficiary and under which the Private Company shall issue up to $100 million of Convertible Secured Promissory Notes (the “Private Company Notes”) to the investors at the closing of the Merger Agreement, of which $52.075 million is committed as of the date hereof. In connection therewith, the Company will receive $15.0 million of cash and will issue $15.0 million of unsecured notes (the “Advance Notes”) for the purpose of providing working capital to the Company on May 30, 2023. At the closing of the merger, the Advance Notes shall automatically be exchanged for Private Company Notes issued by Private Company, with the principal balance of the Advance Notes plus all accrued interest being credited towards the Private Company Notes principal amount on a dollar-for-dollar basis. Under the terms of the Merger Agreement, the Company may solicit alternative acquisition proposals from third parties during a 30-day “go-shop” period beginning on the date of the Merger Agreement. There can be no assurances that the “go-shop” will result in a superior proposal. The Company does not intend to disclose developments related to the solicitation process until it determines whether such disclosure is appropriate or is otherwise required. The Bidder states in the Proposal that, while the Proposed Transaction would not be subject to a financing condition to pay the purchase price in the Proposed Transaction, the Bidder’s expectation is that, concurrent with the consummation of the Proposed Transaction, Buyer or its affiliates would complete a financing for purposes of raising funds to operate the Issuer after the Proposed Transaction. In addition, the Bidder states in the Proposal that the Proposal is conditioned on certain other to be identified Issuer stockholders agreeing to roll their existing equity into Buyer in the Proposed Transaction. The terms of any potential agreement between GreenLight and Fall Line would be contingent on certain conditions, including completion of due diligence review and negotiation of definitive transaction documents, as well as certain to be identified Company stockholders agreeing to roll their existing equity in connection with the Proposed Transaction. No assurance can be given that a definitive transaction with respect to Fall Line’s indication of interest or any other potential transaction will eventually be consummated. The transaction was negotiated on behalf of the Company by a Special Committee of its Board of Directors (the “Special Committee”) composed entirely of independent directors with the assistance of independent financial and legal advisors. Following the Special Committee’s unanimous recommendation, the Company’s Board of Directors unanimously approved the Merger Agreement and has recommended that the Company’s stockholders tender their shares of Company Common Stock in the Offer. Subject to customary closing conditions, the Company expects the transaction to close in the third quarter of 2023. As of July 19, 2023, a total of 18,791,264 Shares were validly tendered and not validly withdrawn pursuant to the Offer as of the Expiration Date, representing approximately 60.36% of the outstanding Shares other than Rollover Shares. As of the expiration of the Offer, the number of Shares validly tendered and not validly withdrawn pursuant to the Offer satisfied the Minimum Condition. As of June 21, 2023, the offer is scheduled to expire on July 19, 2023. Goodwin Procter LLP acted as legal advisor to GreenLight Biosciences Holdings in the transaction. Roth Capital Partners, LLC is serving as financial advisor and Foley Hoag LLP is serving as legal counsel to the Special Committee. O’Melveny & Myers LLP is serving as legal counsel to Fall Line. ROTH Capital Partners, LLC acted as fairness opinion provider to the special committee. Continental Stock Transfer & Trust Company acted as depositary to GreenLight. A group of buyers led by Fall Line Endurance Fund, Lp, managed by Fall Line Capital, LLC completed the acquisition of GreenLight Biosciences Holdings (NasdaqGM:GRNA) from stockholders on July 24, 2023.
Reported Earnings • May 11First quarter 2023 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2023 results: US$0.19 loss per share (improved from US$0.34 loss in 1Q 2022). Revenue: US$3.82m (up US$3.56m from 1Q 2022). Net loss: US$28.5m (loss narrowed 26% from 1Q 2022). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 30%. Revenue is forecast to grow 51% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Biotechs industry in the US.
Reported Earnings • Mar 30Full year 2022 earnings: EPS in line with analyst expectations despite revenue beatFull year 2022 results: US$1.27 loss per share (further deteriorated from US$1.17 loss in FY 2021). Net loss: US$167.1m (loss widened 49% from FY 2021). Products in clinical trials Phase I: 6 Phase II: 2 Post-clinical trial products Pre-registration: 2 Revenue exceeded analyst estimates by 156%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 67% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Biotechs industry in the US.
공시 • Feb 03Rwanda FDA approves Platform Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccinePlatform Life Sciences signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that has been approved by the Rwanda FDA. The trial will be performed by leading clinical investigators in Rwanda, in partnership with Platform Life Sciences. Rwandan scientific leaders have conducted several clinical trials for large pharmaceutical companies and are at the forefront of advancing end-to-end research and development in Africa. Platform Life Sciences has built an innovative global partnerships network for executing clinical trials with modern technology and infrastructure that has the potential to lower costs and accelerate the time to market for products. The network has expertise in COVID-19, vaccines, viral respiratory, and other infectious diseases.
공시 • Feb 02Greenlight Biosciences Holdings Receives Approval to Initiate Phase I/II Clinical Trial of Covid-19 Mrna Vaccine CandidateGreenLight Biosciences Holdings announced that it has received regulatory approval from the Rwanda Food and Drugs Authority (Rwanda FDA) to start a Phase I/II clinical trial of its vaccine candidate against Covid-19, as a booster to previously vaccinated individuals. Preparations for the trial are underway.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Nov 11Third quarter 2022 earnings released: US$0.27 loss per share (vs US$9.86 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share. Net loss: US$38.2m (loss widened 14% from 3Q 2021). Revenue is forecast to grow 121% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Seeking Alpha • Oct 12GreenLight Biosciences cutting 25% of staff as part of realignmentGreenLight Biosciences (NASDAQ:GRNA)is eliminating 25% of its workforce as part of a realignment to support R&D in its research, development and commercialization of its plant health and human health pipelines. On the human health front, the company will focus on proof of concept of its technology platform with its COVID vaccine and advancing ITS shingles program in collaboration with THE Serum Institute of India. Regarding plant health, GreenLight (GRNA) will continue to advance fungicides and insecticides in its pipeline.
Recent Insider Transactions • Aug 17Independent Director recently bought US$250k worth of stockOn the 11th of August, Matthew Walker bought around 64k shares on-market at roughly US$3.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 16Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.28 loss in 2Q 2021)Second quarter 2022 results: US$0.42 loss per share (down from US$0.28 loss in 2Q 2021). Net loss: US$51.9m (loss widened 91% from 2Q 2021).
공시 • Aug 13GreenLight Biosciences Holdings announced that it expects to receive $109.149981 million in funding from a group of investorsGreenLight Biosciences Holdings announced a private placement of 27,844,383 common shares at a price per share of $3.92 for gross proceeds of $109,149,981 on August 12, 2022. The transaction will include participation from accredited investors, existing institutional investors and new investors including Cummings Foundation, Inc., Endowment Arm, the FTX Foundation, Insud Pharma S.L.U., Rivas Capital LLC, Sigmas Group, SymBiosis Capital Management LLC, returning investors S2G Ventures, Bnp Paribas Funds - Ecosystem Restoration; a fund managed by BNPP Asset Management Luxembourg, Continental Grain Company Corp., Cormorant Asset Management, LP, Fall Line Capital, LLC, Morningside Ventures Limited, and certain directors and executive officers of the company.
Seeking Alpha • Aug 12GreenLight Biosciences launches $109M in financingGreenLight Biosciences (NASDAQ:GRNA) announced a private placement of ~$109M; financing includes participation from new and existing institutional investors. The company has agreed to sell ~27.8M shares to a select group of institutional and accredited investors at $3.92/share. The company plans to use the net proceeds from the financing to advance its development of research and commercial programs and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash and equivalents, is expected to be sufficient to fund operations through the 1H23. Shares trading 2.8% higher premarket.
공시 • Aug 02GreenLight Biosciences and Samsung Biologics Completes First Commercial-Scale Engineering Run for mRNA Covid-19 VaccineGreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership. Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability. GreenLight's process—from drug substance and lipid nanoparticle formulation to bulk drug product—can be completed in the same facility, an important capability. GreenLight's mRNA synthesis reaction had a titer of 12g/L at commercial scale and produced 650g of mRNA. The company's RNA platform allowed GreenLight to move from conceptualizing an mRNA vaccine to delivering released clinical trial material in less than two years. With the demonstration at Samsung, and with GreenLight's Covid booster vaccine clinical trial expected to start in 2022, GreenLight would be capable of supplying mRNA vaccine at a commercial scale.
Board Change • Aug 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Seeking Alpha • Aug 01GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccineGreenLight Biosciences (NASDAQ:GRNA) and partner Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies' mRNA COVID-19 vaccine. After the announcement of the partnership, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months. The companies said commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product. (GRNA) is up 3.6%.
Board Change • Jul 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • May 18First quarter 2022 earnings released: US$0.34 loss per share (vs US$0.27 loss in 1Q 2021)First quarter 2022 results: US$0.34 loss per share (down from US$0.27 loss in 1Q 2021). Net loss: US$38.2m (loss widened 49% from 1Q 2021).
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 23High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Eric O’Brien was the last director to join the board, commencing their role in 2019. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Apr 05GreenLight Biosciences: Synthesizing Cell-Free RNAGreenLight Biosciences makes affordable and accessible RNA products for human health and agriculture. The company’s cell-free RNA manufacturing platform allows for cost-effective and scalable production of RNA. The company became a publicly listed and Public-Benefit Corporation following a business combination in February 2022.
공시 • Mar 30GreenLight Biosciences Appoints Barney Graham as Human Health Scientific Advisory BoardGreenLight Biosciences announced Barney Graham to its Human Health Scientific Advisory Board. The former deputy director of the NIAID Vaccine Research Center, Dr. Graham is an immunologist, virologist, and clinical trials physician with an extensive background in basic and translational research applied to vaccine development. He is best known for his research on respiratory syncytial virus (RSV), influenza, coronaviruses, HIV, and other emerging viral diseases. Until his retirement last year, Dr. Graham was the chief of the Viral Pathogenesis Laboratory and Translational Science Core. He was named one of the world’s 100 most influential individuals and one of the Heroes of the Year in 2021 by Time magazine for his role in developing the COVID-19 vaccine. He was also recognized as the Federal Employee of the Year by the Partnership for Public Service. Dr. Graham is an author on more than 500 scientific publications and a thought leader on emerging viral diseases and pandemic preparedness. He was involved in the advanced evaluation of vaccines and monoclonal antibodies for HIV, Ebola, and Chikungunya. He also developed novel vaccines for RSV, influenza, Zika, paramyxoviruses, and coronaviruses including the first COVID-19 vaccine and monoclonal antibody to enter clinical testing and that subsequently achieved Emergency Use Authorization and licensure.
공시 • Feb 08GreenLight Biosciences Holdings Announces Management ChangesOn February 2, 2022, Environmental Impact Acquisition Corp. (ENVI), consummated the previously announced business combination with GreenLight Biosciences Inc. (GreenLight), pursuant to the terms of the business combination agreement, dated August 9, 2021 (the Business Combination Agreement), among ENVI, GreenLight and Honey Bee Merger Sub Inc. (“Merger Sub). Pursuant to the terms of the Business Combination Agreement, Merger Sub merged with and into GreenLight, with GreenLight surviving the merger as a wholly owned subsidiary of ENVI (the Merger or Business Combination). In connection with the consummation of the Merger on the Closing Date, ENVI changed its name to GreenLight Biosciences Holdings, PBC (GreenLight Holdings) and became a public benefit corporation. Effective upon the Closing, and in accordance with the terms of the Business Combination Agreement, each of Daniel Coyne, Marc Marano, Deval L. Patrick, David Brewster and Dean Seavers ceased serving as a director of GreenLight Holdings, and each of Daniel Coyne and Marc Marano ceased serving as an executive officer of GreenLight Holdings.
Board Change • Feb 05No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Board Observer Colin Steen was the last director to join the board, commencing their role in 2019. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.